The Korean media reports that Teva is one of several pharmaceuticals giants in talks to acquire Celltrion.
The share price of Korean company Celltrion Inc rose nearly 10% on the Seoul Stock Exchange yesterday after reports in the South Korean media that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) was one of several pharmaceutical giants in talks to acquire the biotech firm. Reports named Roche Holding AG, and AstraZeneca Plc. as also holding acquisition talks with Celltrion.
Celltrion, one of Korea's largest biotech firms, and the largest firm listed on Korea's second-tier KOSDAQ market, said last week that its biggest shareholder is in talks with interested parties to sell a controlling stake in the company.
Celltrion declined to comment on the reports.
Published by Globes [online], Israel business news - www.globes-online.com - on January 8, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2014